David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

At the preferred starting point, about 3 cm above the esophagogastric junction, the esophageal wall is usually normal. As a rule, I do not open the entire longitudinal layer first and then the ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data from Part B of the DeFianCe study ...

Despite the set back in advanced gastric cancer, the company announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab (DKN-01) in combination with bevacizumab and ...

The primary end point was overall survival ... Thoracoabdominal esophagectomy was performed for esophageal tumors and for esophagogastric junction tumors extending into the esophagus.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

A combination of camrelizumab with nab-paclitaxel (Abraxane), oxaliplatin, and fluorouracil (Nab-POF) resulted in safe conversion rates and high efficacy responses at 3 years in patients with gastric ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Together, these results point to a clinically meaningful synergy between ... compared to TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer who have previously ...

Together, these results point to a clinically meaningful synergy between ... compared to TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer who have previously ...